[The evaluation of thyroid suppression test in predicting the outcome of Graves' disease treated by short-term antithyroid drugs]

One hundred and fifteen new patients with Graves' hyperthyroidism were received thyroid suppression test after cessation of 6 month course of drug therapy. The results of follow up for another 12 months were that one of them had lost, 48 cases were in remission, and 66 cases had relapsed. The present study shows that thyroid suppression test, including the 4th, 6th and 24th hour suppression rates, is useful in predicting the outcome of drug therapy. The effect of 6th hour suppression rate is better than that of 24th and 4th hours, with 75.8% sensitivity, 75.0% specificity and 75.4% accuracy when 30% of thyroid suppression rate is as out-off point which is decided by ROC curve. It is suggested that 6 hour 30% suppression rate is better than the traditional 24 hour 50% suppression rate in the prediction of outcome of drug therapy.

[Chemical constituents in the stem of Premna crassa Hand. -Mazz]

In this paper four compounds isolated from the stem of Premna crassa are described. Their structures have been identified as friedelin, epifriedelanol, stearic acid and beta-sitosterol respectively by comparing their chemical and spectroscopic data with those of the authentic samples.

Physical mapping of the human chromosome 11q23 region containing the ataxia-telangiectasia locus

Two breakpoints within chromosome 11q23 were characterized with 29 DNA probes to establish a physical map of the region. This region is notable in that it contains at least 14 functional genes which are also syntenic in the mouse (chromosome 9). Chromosome 11q23 includes these markers: STMY, CLG, NCAM, DRD2, APOA1, APOC3, APOA4, CD3E, CD3D, CD3G, PBGD, THY1, ets-1, and cbl-2. The two breakpoints, herein called "X;11" and "4;11," defined a region of approximately 8 cM containing the APO and CD3 complexes as well as the polymorphic marker D11S29. DRD2 localized centromeric to the X;11 breakpoint despite evidence for close genetic linkage to D11S29, suggesting that DRD2 lies close to the X;11 breakpoint. THY1, PBGD, and cbl-2 localized telomeric to the 4;11 breakpoint and thus to the [D11S29--APO--CD3] grouping as well. The physical map helps to correlate the cytogenetic and linkage maps of this region. It also suggests that the human 11q23 syntenic grouping is inverted with respect to its murine counterpart. Based on this physical map and on our primary linkage map of the 11q23 region, we are able to confirm a preliminary localization of the gene for ataxia-telangiectasia group A (ATA) to a region centromeric to the interval defined by D11S144 (pYNB3.12) and THY1.

[Observation of the outcome of 112 cases with Graves' disease treated by short-term antithyroid drug therapy for one year]

One hundred and twelve new cases with Graves' disease were treated by tapazole for 6 months and followed-up for another 12 months in a prospective study. One hundred and eleven cases completed the whole course of study, and only one failed to be followed up. The results of the follow-up for 12 mon showed that the remission rate was 41.4% (46/111) and relapse rate was 58.6% (65/111). The present study indicated that the remission or relapse was related with serum levels of T3 before treatment, shrank goiter and disappearance of goiter bruit during the treatment as well as thyroid suppression rate, but not related to sex, age, period of illness before therapy or severity of the disease. It is suggested that a 6-mon antithyroid drug therapy instead of traditional long term therapy may be suitable for those patients who are with a reduced goiter and disappeared goiter bruit during the antithyroid therapy, and suppressible thyroid up-take by T3 and whose serum levels of T3 before treatment are not very high. So the patients may benefit from the short-term therapy. They are not only able to obtain a prolonged remission but also save time and money.

A primary linkage map of the human chromosome 11q22-23 region

We have constructed a genetic map of the human chromosomal region 11q22-23 by multipoint linkage analysis of 13 DNA polymorphisms that we have condensed into eight loci. An analysis for linkage disequilibrium between tightly linked probe/enzyme systems allows us to make specific recommendations for future DNA typing at these loci. The resulting sex-averaged multipoint map spans approximately 80 cM and differs considerably from previously reported genetic maps of this region. Our mathematically derived "most likely order" of the markers is compatible with physical mapping data using somatic cell hybrids. The known localizations of at least 14 functional genes and several disease loci to 11q22-23, including ataxia telangiectasia, make the mapping of this region especially relevant to studies of disease pathogenesis.

DNA polymorphism in the human Thy-1 gene

Thy-1 is a membrane glycoprotein expressed predominantly in brain tissue and occasionally in lymphoid tissue. The human Thy-1 gene is located on chromosome 11q22.3. Although two allelic forms of Thy-1 exist in mice (Thy-1.1 and Thy-1.2), no allelic forms have been described for the human Thy-1 gene. We describe a polymorphic MspI site within the human Thy-1 gene that distinguishes two alleles, 8 and 9, which are represented in a northern European population at frequencies of 0.7 and 0.3, respectively. Thy-1, therefore, provides a potentially useful marker to identify linkages with human disease genes located near 11q22.